Global Cardiac Mapping Market is projected to grow at a CAGR of 9.46%

cardiac mapping market

Rising incidences of congenital ailments, growing occurrences of non-communicable diseases Viz. Cardiovascular diseases, the increasing proportion of the aging population, profuse R&D investments among others are anticipated to propel the market to stratospheric heights. 

As per the report, the market pertaining to the global cardiac mapping market is expected to reach US$1,527.102 million by 2025.

A few examples of market developments by a select few players operating in the global cardiac mapping market which are being mentioned below are an attestation of the upward direction of the global cardiac market growth.

January 2019 – FDA Approval

Abbott (NYSE: ABT) had reportedly announced the approval of the TactiCath™ Contact Force Ablation Catheter by the U.S. Food and Drug Administration (FDA), Sensor Enabled™, a new ablation catheter. It was reportedly designed to aid physicians so that atrial fibrillation (AFib) can be treated accurately and effectively. This approval reportedly expands the organization’s portfolio of cardiac ablation tools that reportedly integrates with the organization’s EnSite Precision™ cardiac mapping system enabling physicians to develop images of the heart during cardiac ablation procedures which are more precise.

January 2019 – Signing of Agreement

BioSig Technologies, Inc. (NASDAQ: BSGM) had reportedly signed an agreement with the Mayo Clinic to conduct first-in-human studies using the PURE EP System. These studies were reported to be conducted with the rationale to validate the safety and efficacy of the PURE EP System during mapping and ablation procedures in the cardiac EP lab.

April 2019 – Technological Integration

Stereotaxis, Inc. and Acutus Medical, Inc. have reportedly announced the successful treatment of first patients utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The technological integration has been cleared for use in Europe with additional regulatory clearances expected in the coming months. This procedure which is a therapeutic one has reportedly combined high-resolution real-time cardiac imaging and mapping from Acutus’ AcQMap system and the precision and stability of the Stereotaxis Robotic Magnetic Navigation system, enabling physicians to clearly see a patient’s arrhythmia pattern and then reach those targets to deliver therapy with the accuracy of robotic navigation. 

May 2019 – Product Launch

Johnson & Johnson’s (NYSE: JNJ) Medical Device Business Services, Inc. had reportedly launched Biosense Webster Inc.’s CARTONET which is reportedly a part of the company’s mission to facilitate the revolutionizing of the manner in which data is shared and leveraged by researchers, hospitals, health systems, and electrophysiologists to enhance patient outcomes and operational efficiency in catheter ablation procedures. 

May 2019 – Partnerships

An announcement of a reported collaboration by Royal Philips (AMS: PHIA) with Medtronic (NYSE: MDT) to promote the advancements of the treatment of paroxysmal atrial fibrillation (PAF) was made. PAF is known to be a common heart rhythm disorder.Medtronic was reported to facilitate sales of products on behalf of Philips to extend an integrated and innovative image guidance solution for cryoablation procedures through this agreement.  Further, the novel KODEX-EPD cardiac imaging and navigation system will be brought to the market by Philips. The system is known to be equipped with cryoablation specific features that reportedly facilitates cryoablation procedures by electrophysiologists with a reduced need for X-ray imaging.

August 2019 – FDA Clearance

A company that deals with the reprocessing of single-use cardiology medical device called Innovative Health has reportedly received for reprocessing the Webster Duo-Decapolar Diagnostic EP Catheter by U.S. Food and Drug Administration (FDA) clearance. Reportedly used in the electrophysiological mapping of cardiac structures, such as in Atrial Fibrillation procedures it’s essentially a 20-electrode EP catheter that is. This also reaffirms the emergence of the single-use device reprocessing industry as a vital link in the medical device industry’s supply chain by focusing on making these “single-use” devices available for another use, which evidently will reinforce the growth of the cardiac mapping market.

November 2019 – Partnership

Innovative Health and Acutus Medical, Inc. have reportedly announced a partnership that challenges the status quo in electrophysiology by offering advanced technology to improve patient outcomes cost-effectively. The two venture-backed companies have been reported to team-up to offer a comprehensive suite of electrophysiology (EP) products, to hospital customers.  

As a part of the report, the major players operating in the global cardiac mapping market, which have been covered are Medtronic, Catheter Precision, Inc., Boston Scientific Corporation, BIOTRONIK SE & Co KG, Biosense Webster, Inc., Baylis Medical Company, Inc., Acutus Medical and Abbott.

View a sample of the report or purchase the complete study at

This report segmented the global cardiac mapping market on the basis following terms

  • By  Product
    • EP Ablation Catheters
    • EP Laboratory Devices
    • EP Diagnostic Catheters
    • Access Devices
  • By Indication
    • Atrial Fibrillation
    • Atrial Flutter
    • Atrioventricular Nodal Reentry Tachycardia
    • Wolff-Parkinson-White Syndrome
  • By End-User
    • Hospitals and Clinics
    • Diagnostic Centres
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Others